CHEK1 and non-small cell lung carcinoma: These results support the findings presented above with NSCLC cell lines and suggest that decreased Chk1 and phospho-cdc2 (Tyr15) levels may be sensitive pharmacodynamic markers for HDACi efficacy in patient tumor samples to predict and assess patient response to HDACi treatment in clinical studies.